Scancell (SCLP) Hits New 52-Week Low at $7.50

Scancell Holdings Plc (LON:SCLP) reached a new 52-week low during trading on Wednesday . The company traded as low as GBX 7.50 ($0.10) and last traded at GBX 8 ($0.10), with a volume of 407809 shares. The stock had previously closed at GBX 7.75 ($0.10).

COPYRIGHT VIOLATION WARNING: “Scancell (SCLP) Hits New 52-Week Low at $7.50” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at

About Scancell (LON:SCLP)

Scancell Holdings plc, a biopharmaceutical company, engages in the discovery and development of novel monoclonal antibodies and vaccines for the treatment of cancer based on its ImmunoBody and Moditope platforms in the United Kingdom. Its products include SCIB1, a plasmid DNA vaccine, which is in Phase I/II clinical trials for the treatment of melanoma; SCIB2 to treat lung cancer antigen; and Modi-1, which is in the pre-clinical development to treat triple negative breast cancer, ovarian cancer, and sarcoma.

Featured Article: Buyback For Investors Defined

Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with's FREE daily email newsletter.

Leave a Reply